Uninvestigated dyspepsia refers to patients with new or recurrent dyspeptic symptoms in whom no investigations have previously been undertaken. These patients are much more likely to present in primary than in secondary care. It is particularly important to be able to offer effective symptom relief to support the explanation, reassurance, and advice provided to patients, and low dose or standard dose proton pump inhibitor therapy appears to offer the most effective approach to empirical therapy of this kind.
- primary care
- uninvestigated dyspepsia
Statistics from Altmetric.com
Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The author of this paper has recieved sponsorship for travel and an honorarium from AstraZeneca.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.